Production (Stage)
Akebia Therapeutics, Inc.
AKBA
$2.86
$0.031.06%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 133.98% | -3,814.01% | -38.30% | 23.20% | 33.08% |
| Total Depreciation and Amortization | -96.65% | -0.59% | -0.35% | 0.03% | -0.36% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 124.58% | 2,467.55% | 448.09% | 8.44% | 39.29% |
| Change in Net Operating Assets | -96.25% | 80.06% | -82.00% | -576.86% | -376.92% |
| Cash from Operations | 30.08% | -93.50% | 6.59% | -377.38% | -10.80% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -72.97% | -- | -- | -- | -- |
| Total Debt Repaid | 98.74% | 100.01% | -- | 95.33% | -129.54% |
| Issuance of Common Stock | 245.45% | 232.70% | 3,390.00% | -- | 55,638.24% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 91.60% | -- | -- | -- | -- |
| Cash from Financing | 305.64% | 1,830.62% | 2,346.00% | 195.50% | 215.71% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 6,527.27% | 596.30% | 23.09% | 43.83% | 97.14% |